Can a vaccine boost TB treatment? new trial aims to find out
NCT ID NCT06205589
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental vaccine called ID93 + GLA-SE in 1500 people with drug-susceptible pulmonary TB. Participants receive the vaccine or a placebo alongside their regular TB treatment. Researchers want to see if the vaccine can improve immune responses and reduce poor outcomes like treatment failure or TB coming back. It is the first time this vaccine is tested in people living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ID93 + GLA-SE vaccine
- What this could lead to
- If successful, this vaccine could become an add-on to standard TB treatment, reducing treatment failure and TB recurrence.
- What could go wrong
- This is a Phase 2 trial, so it is still early. The vaccine may not prove effective or safe in larger populations, and results may not apply to all TB patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New rapid test could free TB patients from isolation sooner
- New TB cocktail aims to shorten treatment
- AI stethoscope aims to cut unnecessary antibiotics in kids with cough
- Pee test could spot TB patients skipping meds
- Could aspirin or ibuprofen help beat TB faster?
- Exercise program aims to boost lung health in TB survivors